Abstract
Esophageal cancer is one of the most aggressive and lethal gastrointestinal tract malignancies, with a poor overall five-year survival rate. Cordycepin, a major compound of Cordyceps sinensis, has been shown to have anticancer potential. This study focuses on the anticancer properties of cordycepin that target esophageal cancer and reveals molecular aspects underlying these effects. In our CCK-8 assays and colony formation assays, cordycepin significantly suppressed esophageal cancer cell proliferation. Moreover, cordycepin induced chromatin condensation in esophageal cancer cells and significantly increased the number of apoptotic cells through activation of caspase cascades, apoptotic signaling, and the regulation of Bcl-2 family members. Cell cycle assays showed that cordycepin altered cyclin-dependent kinase1 and cyclinB1 expression, which resulted in a G2/M phase blockade. Mechanistically, ERK pathway inactivation was involved in the anti-tumor functions of cordycepin. The same results were also observed in vivo. Taken together, these findings reveal that cordycepin induces pro-apoptosis and anti-proliferation mechanisms in cancer cells, and may represent a novel therapeutic agent.
Introduction
Esophageal Squamous Cell Carcinoma (ESCC) accounts for over 90% of esophageal cancer cases globally. It is a highly aggressive malignancy, often diagnosed at advanced stages, leading to a dismal five-year survival rate of approximately 15%. Despite advancements in surgery and chemotherapy, tumor recurrence and treatment resistance remain significant hurdles. Consequently, there is an urgent need for novel, effective, and low-toxicity therapeutic agents.
Cordycepin (3′-deoxyadenosine), a bioactive compound derived from the "caterpillar fungus" (Cordyceps sinensis) used in traditional Chinese medicine, has emerged as a promising candidate. This study investigates the anti-cancer efficacy of cordycepin against ESCC and elucidates the underlying molecular mechanisms, specifically focusing on cell cycle arrest and apoptosis mediated by the ERK signaling pathway.
Methods
The researchers employed a comprehensive experimental framework to evaluate cordycepin:
- In Vitro Analysis: Human ESCC cell lines (ECA109 and TE-1) and a control "normal" line (HEK-293T) were treated with cordycepin. Proliferation was assessed using CCK-8 and colony formation assays.
- Flow Cytometry: Used to quantify apoptosis and determine cell cycle distribution.
- Molecular Profiling: Western blotting measured protein levels of key regulators, including Bcl-2 family members, Caspases, CDK1, Cyclin B1, and components of the MEK/ERK pathway.
- In Vivo Validation: ECA109 xenografts were established in nude mice (BALB/c-nu/nu) to observe the effects of cordycepin (5mg/kg and 10mg/kg) on tumor growth and systemic toxicity.
- Pathway Inhibition: The ERK inhibitor Sch772984 was used to confirm the role of the MEK/ERK pathway in cordycepin's mechanism of action.
Results
Growth Inhibition and Selective Toxicity
Cordycepin demonstrated significant, dose- and time-dependent inhibition of ESCC cell growth. The IC50 values were determined to be approximately 64.8 μg/mL for ECA109 and 60.6 μg/mL for TE-1. Notably, cordycepin exhibited selective toxicity; while it effectively suppressed cancer cells, it showed no significant inhibitory effect on the normal HEK-293T cell line at comparable doses.
Induction of G2/M Phase Arrest and Apoptosis
The study found that cordycepin does not merely kill cells indiscriminately but induces a specific G2/M phase blockade. This arrest is achieved by downregulating the expression of CDK1 and Cyclin B1, the primary drivers of the G2 to M transition.
Furthermore, cordycepin triggers mitochondrial-mediated apoptosis. It shifts the cellular balance toward cell death by increasing the expression of the pro-apoptotic protein Bax and decreasing the anti-apoptotic protein Bcl-2. This shift leads to the activation of the caspase cascade, specifically Caspase-3, resulting in programmed cell death.
Inactivation of the ERK Pathway
Mechanistically, the anti-tumor effects of cordycepin are linked to the inactivation of the MEK/ERK signaling pathway. In many cancers, this pathway is constitutively active, promoting uncontrolled proliferation. Cordycepin treatment effectively suppressed ERK phosphorylation, thereby "turning off" this critical growth signal.
In Vivo Efficacy and Safety
In the mouse xenograft model, cordycepin treatment (10 mg/kg) resulted in a dramatic reduction in both tumor volume and weight. Importantly, the treatment appeared well-tolerated; histological examination of the liver showed no signs of organ damage, suggesting a favorable safety profile for systemic administration.
Discussion and Conclusion
This research highlights cordycepin as a potent anti-cancer agent against esophageal squamous cell carcinoma. By inducing G2/M arrest and apoptosis through the inhibition of the ERK pathway, cordycepin addresses the aggressive nature of ESCC with minimal toxicity to normal cells.
While these results are promising, future work should explore the potential synergistic effects of cordycepin when combined with standard chemotherapeutics like cisplatin. Additionally, clinical trials are necessary to validate these findings in human patients and to fully map the complex signaling networks involved beyond the ERK pathway.
Summary updated